Safety and efficacy of non-absorbable mesh in contemporary gynaecological surgery by Izett, ML et al.
REVIEW ARTICLE Open Access
Safety and efficacy of non-absorbable mesh
in contemporary gynaecological surgery
Matthew Izett1,2*, Anthony Kupelian1 and Arvind Vashisht1,2
Abstract
Mesh-augmented pelvic floor surgery evolved to address the limitations of native tissue repair in reconstructive
surgery. The development of the synthetic mid-urethral tape signalled a revolution in the treatment of stress urinary
incontinence, whilst the use of mesh in abdominal apical prolapse repair may confer benefits over native tissue
alternatives. However, these procedures can be associated with mesh-specific complications, underlining the need
for shared decision-making between physicians and patients prior to mesh surgery.
Transvaginal non-absorbable mesh implants for pelvic organ prolapse are associated with a high risk of serious
adverse events, leading to withdrawal or restricted use in many countries. Increased scrutiny has led to growing
concerns about complications associated with all types of mesh-augmented reconstructive surgery, attracting
widespread media attention.
National and international reports have been commissioned examining the safety and efficacy of mesh surgery in
gynaecology. They have all highlighted systemic failures in the development, regulation and clinical adoption of
medical devices. The widespread application of novel devices prior to the availability of reliable safety and efficacy
data, and delayed recognition of adverse events, is of serious concern. Notwithstanding, the available data continue
to support a role for mesh augmentation. This review outlines the evolution of gynaecological mesh, the safety and
efficacy of pelvic floor surgery using non-absorbable mesh materials, and an overview of specific complications.
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Introduction
Gynaecological mesh refers to synthetic mesh materials
used to augment the surgical repair of pelvic organ pro-
lapse (POP) or stress urinary incontinence (SUI). These
common conditions impair quality of life (QoL) and
have associated healthcare costs. Whilst many women
pursue conservative management initially, surgery is
common. The lifetime incidence of surgery for SUI or
POP by the age of 80 is 11.1% [1]. Traditional surgical
techniques for the treatment of POP and SUI have
well-recognised limitations. Transvaginal native tissue
repair of POP is associated with a significant risk of re-
currence, in the region of 30% [1]. Colposuspension, an
abdominal procedure for SUI, has significant morbidity
and is associated with the development of posterior
compartment prolapse. These limitations fostered the
development of surgical mesh applications to treat POP
and SUI.
The principal applications of gynaecological mesh in-
clude transvaginal mesh (TVM) for SUI, TVM for POP,
and transabdominal mesh for POP. The synthetic
mid-urethral tape (MUT) has been the most common
application of TVM for SUI. Approximately 3.7 million
women underwent insertion of an MUT between 2005
and 2013 [2, 3]. Mesh used to surgically treat POP may
be inserted either vaginally or abdominally, an important
distinction due to significant differences in complication
profiles and adverse events (AEs). Transabdominal mesh
can be used to treat prolapse of the uterus or for
post-hysterectomy vault prolapse (PHVP). Sacrohystero-
pexy suspends the uterus from a sacral anchor point,
whilst sacrocolpopexy similarly suspends the vaginal
vault. In contrast, TVM for POP uses a vaginal approach
to implant a specific device or a mesh inlay at
colporrhaphy.
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It is now clear that some women experience AEs asso-
ciated with mesh procedures. In this review, the term
mesh refers to synthetic, non-absorbable mesh used in
gynaecological surgery and focuses on the evidence for
these procedures, reflecting recent controversy. Absorb-
able mesh materials deserve further research however,
they are beyond the scope of this review. Several na-
tional and international reports have examined the safety
and efficacy of gynaecological mesh [4–7]. These reports
have supported the safety and efficacy of the MUT for
SUI, and transabdominal mesh for POP. However fur-
ther research is required, and critics raise legitimate con-
cerns about a lack of surveillance data and
underreporting of serious adverse events (SAEs). In Eng-
land, concerns have led to a pause in the use of mesh for
SUI, pending further review [8]. None of the mesh reports
have supported TVM for primary repair of POP outside
of the research setting, and in some countries, TVM has
been banned outright [9]. Given the potential for
mesh-related morbidity and the complexity of managing
mesh complications, a contemporary evidence-based ap-
proach is important for clinicians managing pelvic floor
disorders. This article documents the development of
mesh-augmented gynaecological surgery and reviews the
evidence supporting safety and efficacy to guide clinicians.
History of mesh
A range of materials and devices are covered by the term
‘mesh’, defined by the International Urogynecological As-
sociation (IUGA) and International Continence Society
as ‘a (prosthetic) network fabric or structure; open
spaces or interstices between the strands of the net’ [10].
Mesh is differentiated from a graft, which is typically a
product derived from biological tissue. Surgical mesh
was originally developed to augment abdominal hernia
repair. A range of materials were used prior to the ad-
vent of plastics and ultimately polypropylene, which was
first used to repair inguinal hernias in the 1960s [11].
Strengthening native tissue repair with mesh appeared
to translate well to the surgical treatment of pelvic floor
disorders. Contemporary mesh procedures are based on
historical operations that utilised native tissue or suture
material.
Some 150 surgical procedures for urinary incontinence
have been described. Von Giordino is credited with
undertaking the first pubovaginal incontinence sling, uti-
lising gracilis muscle grafted around the urethra [12].
The use of synthetic material to do this was first de-
scribed in 1965, and in 1996, the US Food and Drug Ad-
ministration (FDA) approved the ProteGen™ sling to
treat SUI [13, 14]. Work based on the integral theory
undertaken by Petros and Ulmsten in the 1980s led to
the development of the most popular MUT, the
tension-free vaginal tape (TVT) [15]. The integral theory
proposed that pelvic floor dysfunction resulted from lax-
ity of the vagina or supporting ligaments as a result of
connective tissue weakness [16]. Initial studies utilised
mersilene which was associated a 14% risk of erosion.
The technique was refined and polypropylene adopted,
leading to FDA approval in 1998 [17]. Subsequent stud-
ies showed equivalent efficacy to colposuspension whilst
avoiding laparotomy, and the MUT quickly became the
‘gold standard’ treatment for SUI [3, 18]. The original
TVT was inserted via the retropubic route (RPR), al-
though variations include the transobturator route
(TOR) and the ‘mini-sling’.
The surgical management of POP with mesh includes
a variety of approaches and techniques. Surgeons may
use a vaginal or abdominal approach, with the latter be-
ing developed in the mid-twentieth century. Uterine pre-
serving abdominal hysteropexy utilises either sutures or
mesh, with suspension to pelvic ligaments or the sacral
promontory. The evolution of mesh hysteropexy is out-
lined in Table 1.
For women who have undergone hysterectomy, the re-
ported incidence of PHVP is as high as 43%, with the rate




Open abdominal approach. The uterus is sutured to the anterior
abdominal wall at the level of the cervix using the peritoneum.
1891 Donald and Shaw
‘Manchester Repair’
Vaginal approach. Anterior and posterior colporrhaphy with
amputation of cervix [80].
1956 Arthure and Savage
‘Suture sacral hysteropexy’
Open abdominal approach. The uterine fundus or posterior
uterine corpus is sutured to the ligamentous tissue of the
sacral promontory [81].
1979 SK Chaudhuri
‘Abdominal autologous fascial uterine sling’
Fascial sling from external oblique is brought through the
transversalis fascia and sutured to the anterior aspect of the cervix [82].
1993 Andrew Farkas
‘Mesh hysterosacropexy’
Open abdominal approach. Goretex mesh is used to fix
the uterus to the sacrum [83].
2010 Price and Jackson
‘Laparoscopic hysteropexy’
Laparoscopic approach. Bifurcated polypropylene mesh is
wrapped round the uterus through the broad ligament and
suspended to the sacral promontory [84].
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of surgical repair between 6 and 8% [19, 20]. Sacrocolpo-
pexy permits abdominal suspension using mesh. Lane first
described the use of autograft to suspend the vault in
1962 [21]. The first series of polypropylene abdominal
vault suspension procedures was published in 1991 [22].
There are now over 25 years of data examining
mesh-augmented sacrocolpopexy, with meta-analyses
reporting advantages over vaginal alternatives [23]. Now
considered a routine treatment for PHVP, it has been en-
dorsed by the European Commission safety report and
European consensus guidelines, which recommend the
laparoscopic approach [6, 7]. A review of the CARE trial
found concurrent sacrocolpopexy at the time of hysterec-
tomy to be associated with a higher risk of mesh erosion
than for those having the procedure for PHVP, and this
technique is rarely advocated [24].
Transvaginal mesh for prolapse is either placed as a
customisable inlay secured during colporrhaphy, or in-
troduced using a kit or device. Despite a lack of quality
evidence supporting superior outcome, TVM for POP
was rapidly adopted. Mesh kits were constantly rein-
vented, endorsed, and implanted in large volumes prior
to safety concerns being raised. Emerging evidence has
subsequently demonstrated an unacceptable rate of
SAEs associated with TVM. Heneghan et al. have de-
scribed the history of the FDA regulatory process with
respect to TVM devices for POP [13]. As Class II de-
vices approved through the Food and Drug Administra-
tio (FDA’s) 510(k) process, products were marketed on
the basis of ‘equivalence’ to existing devices, despite
minimal clinical data. Limited prospective studies
emerged in the early 2000s, and a host of TVM products
for POP followed with FDA approval [13, 25]. In 2016,
with increasing evidence demonstrating a high risk of
AEs, TVM kits were upgraded to Class III devices.
Post-marketing surveillance was requested and many
TVM kits were withdrawn from the market, leading to a
relatively short-lived period of widespread use [26].
European guidance suggests that TVM should be re-
served for complex recurrent cases [7]. The UK National
Institute and Health and Care Excellence (NICE) states
that TVM for POP should not be used outside the re-
search setting, and some countries such as Australia
have banned TVM completely [9, 27].
Biocompatibility and biophysical profile of mesh
The pathophysiology of mesh erosion or extrusion re-
mains unclear but is likely to be multifactorial. Polypro-
pylene is the most commonly used material as it is
relatively inert, cheap, and easily tailored [28, 29]. The
biocompatibility and biophysical profile of an implant
determines clinical outcomes and complications. Bio-
compatibility, defined as ‘the ability of a material to per-
form with an appropriate host response in a specific
application’, is mediated by tissue integration and host
immunological response [28, 30]. The interplay between
these processes is known as the foreign body response
(FBR) and varies according to the composition of the
implant and individual immunogenic response [31].
Animal studies suggest there is a local implant-mediated
immune response leading to overt or subclinical infection
which may be implicated in mesh erosion or extrusion
[32]. Mesh pore size influences the interaction between
host immunological cells and smaller pathogens. Leuco-
cytes average between 9 and 15 μm whilst a typical bacter-
ium is 2 μm [33]. Small pore size may therefore inhibit
clearance of pathogens within the mesh [34]. Mesh can be
categorised according pore size using the Amid classifica-
tion [33]. Additionally, heavyweight mesh materials have
been found to be less biocompatible; lightweight, macro-
porous mesh is therefore favoured for implants [6].
Fibroblast deposition and granuloma formation associ-
ated with the FBR reduces tissue elasticity and alters tis-
sue adaptation to physical forces. Animal studies have
shown that the presence of mesh reduces biomechanical
tissue compliance leading to stiffness, which may trans-
late clinically into dyspareunia [35]. Transvaginal mesh
has also been shown to alter the structure and function
of vaginal smooth muscle which may be implicated in
the development of AEs attributed to mesh [36]. The
process of excess fibroblast deposition and adaptation to
the extracellular matrix may lead to ‘stress shielding’, al-
tering forces exerted on tissues. Tissues shielded from
dynamic forces may then become thin and atrophy, per-
haps causing mesh erosion or extrusion [37].
Intraoperative variables also alter the biological re-
sponse to mesh. Both animal models and human studies
have shown that reducing the volume of mesh implanted
reduces the risk of erosion [38, 39]. The technique of
mesh placement and its location also influences the like-
lihood of erosion. Ovine models demonstrate a greater
risk of mesh erosion associated with TVM when com-
pared to mesh placed abdominally [40]. Histological
examination of mesh explants in these studies demon-
strated a more pronounced FBR after vaginal placement
perhaps reflecting clinical findings in human studies.
Concerns have also been raised over the malignant po-
tential of mesh. However, a comprehensive review of five
decades of data, during which time millions of implanted
polypropylene mesh devices have been used, did not
demonstrate a link to carcinogenesis [41].
Adverse events attributed to mesh
Mesh-specific AEs should be considered in the context
of complications associated with native tissue surgery, or
indeed no treatment at all. Complications following
mesh-augmented surgery include vaginal mesh erosion
(or exposure), extrusion, pain (affecting the abdomen,
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pelvis, groins, vulva or vagina, and lower limbs), dyspar-
eunia, hispareunia (pain for the partner during sexual
intercourse), infection, urinary voiding dysfunction,
functional bladder and bowel symptoms, and treatment
failure or recurrence [42–44]. There are also reports of
neuromuscular problems, vaginal scarring and implant
shrinkage. Psychological sequelae as a result of physical
problems are common. Whilst the presence of mesh
outside its intended anatomical location is a clearly de-
fined complication, the evidence linking mesh implants
to other AEs is less clear.
To standardise the reporting of AEs associated with
mesh surgery, IUGA has developed a coding system for
the classification of mesh complications, as well as ter-
minology guidance, outlined in Fig. 1 and Table 2 [10].
The most common symptom experienced by those
reporting a mesh complication is pain. Unfortunately,
few studies of gynaecological mesh have used a validated
pain measure pre- and postoperatively. Thus, it is diffi-
cult to accurately determine the incidence of new-onset
pain and more difficult still to confidently attribute pain
to the mesh itself. Of those reporting AEs to the FDA,
38% of complaints reported pain or dyspareunia, and
89% of women reporting complications to the Scottish
review reported pain [44, 45]. The incidence of new
postoperative pain in patients who have undergone a pro-
cedure using gynaecological mesh is reportedly between 0
and 15% [46, 47]. It has been hypothesised that pain may
be generated as a result of mesh contracture over time,
causing tethering of fascia and muscles [48]. Pelvic floor
hypertonia has also been reported in association with TVM
Fig. 1 IUGA classification of complications related directly to the insertion of prostheses (meshes, implants, tapes) or grafts in urogynecological
surgery [10]
Table 2 IUGA terminology [10]
Contraction: Shrinkage or reduction in size
Prominence: Parts that protrude beyond the surface (e.g. due to
wrinkling or folding with no epithelial separation)
Separation: Physically disconnected, for example, vaginal
epithelium.
Exposure: A condition of displaying, revealing, exhibiting or
making accessible (e.g. vaginal mesh visualised
through separated vaginal epithelium)
Extrusion: Passage gradually out of a body structure or tissue
(e.g. a loop of tape protruding into the vaginal cavity)
Compromise: Bring into danger
Perforation: Abnormal opening into a hollow organ or viscus




(Localised) formation of a fistulous tract towards
vagina or skin, where there is no visible implant
material in the vaginal lumen or overlying skin
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[49]. Chronic pain symptoms are likely to be multifactorial,
perhaps initially driven by peripheral nervous system stimu-
lation from the implant. The evolution of chronic pelvic
pain after surgery may involve peripheral and central ner-
vous system ‘centralisation’, with central changes implicated
in the development of regional somatic and visceral pain
symptoms. Referred pain is also commonly reported, be-
lieved to be a result of afferent neurons from different ana-
tomic sites converging, with higher centres being unable to
distinguish between these distinct inputs [50].
Mesh erosion may be asymptomatic or cause local dis-
comfort, discharge and/or pain. In the absence of ero-
sion, the aetiology of pain remains poorly understood.
Some patients with chronic pain will be affected by
mesh erosion or extrusion. For these patients, reasonable
quality evidence supports excisional surgery [51]. In the
absence of erosion or extrusion, there is very limited evi-
dence to direct the management of pain attributed to
mesh. Multi-disciplinary decision-making involving pain
specialists, and careful counselling, are required until
clear evidence-based pathways are developed [4, 45]. A
recent systematic review has attempted to provide a
management framework for mesh complications affect-
ing patients and is discussed later [51].
Systemic Autoimmune Inflammatory Disorders (SAID)
include fibromyalgia, rheumatoid arthritis and lupus,
amongst many other conditions. Although anecdotally at-
tributed to mesh, the background incidence of SAID in
the female population undergoing mesh procedures is
high. In a large study utilising a state-wide registry in the
USA, Chughtai et al. estimated that 41% of women under-
going mesh-augmented surgery had an existing SAID
diagnosis at the time of their operation [52]. In the same
paper, at 6 years follow-up, there was no difference in
rates of SAID amongst 2000 patients undergoing gynaeco-
logical mesh procedures when compared to matched co-
horts undergoing screening colposcopy or vaginal
hysterectomy without mesh. A recent study comparing
30,000 patients with hernia mesh to 70,000 control sub-
jects also failed to illustrate an increased incidence of
SAID in the mesh group [53]. Whilst these data provide
some reassurance that mesh is not associated with SAID
in the medium term, long-term studies are required.
TVM for SUI: safety and efficacy
Over the last decade, transvaginal mesh surgery for SUI
in the form of the MUT has been widely regarded as the
‘gold standard’ surgical intervention for women [3]. It is
the most common procedure performed for SUI and
supported by numerous meta-analyses, and European
and NICE guidelines [7, 54]. Table 3 outlines the sub-
jective cure rates reported in two recent Cochrane re-
views of the surgical management of SUI [55, 56].
A subgroup analysis of randomised controlled trials
(RCT) comparing open colposuspension and MUT dem-
onstrates superior subjective cure rates for the MUT.
Colposuspension is less effective in the medium term (1
to 5 years; relative risk (RR) 1.35; 95% confidence inter-
val (CI) = 1.11–1.64) and long term (more than 5 years;
RR 1.19; 95% CI = 1.03–1.37) [56]. The reviews report
inadequate evidence to make meaningful comparisons
on QoL measures but report that the MUT is more cost
effective than open colposuspension.
Concerning safety, the Cochrane reviews found
favourable short- and mid-term data supporting the
MUT. There was no evidence of a difference in compli-
cation rate as compared to open colposuspension at
medium-term follow-up. The risk of mesh erosion after
both RPR and TOR MUT is around 2% over this
period. The RPR is associated with a higher incidence
of visceral injury and voiding dysfunction. However,
the TOR has significantly higher rates of groin pain
(RR 4.12; 95% CI = 2.71–6.27), and in light of this,
the Scottish mesh report recommended RPR MUT in
preference to TOR [45].
A population study using UK Hospital Episode Statis-
tics by Keltie et al. reported the 5-year complication rate
following a mesh procedure for SUI to be 9.8% [57].
However, this included a wide range of complications,
such as urinary tract infection, that are usually easily
treated and equally common after non-mesh surgeries.
Less than 2.3% of patients required readmission for
complications from mesh surgery and 3.4% of women
underwent readmission for removal or repair. A recent
Scottish national database study supports the favourable
safety profile of the MUT for SUI [58]. Compared with
colposuspension, TVM procedures for SUI have a lower
risk of immediate complications (adjusted relative risk
[aRR] 0·44; 95% CI = 0·36–0·55). The two procedures
carry a similar risk of further incontinence surgery (aRR
0·90; 95% CI = 0·73–1·11) and later complications (aRR
1·12; 95% CI = 0·98–1·27). Some commentators believe
these data convincingly challenge the concerns raised re-
garding TVM for SUI [59]. Although a large body of
high-quality evidence supports safety and efficacy of the
MUT, the volume of surgeries undertaken has generated
significant numbers of women with complications. This
has led to media and political interest, some countries
have banned mesh devices, and others such as England





Retropubic route—MUT [55] 71–97% 51–88%
Transobturator route—MUT [55] 62–98% 43–92%
Colposuspension [56] 69–88% 70%
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have implemented temporary restrictions. The future of
the MUT remains uncertain whilst regulators and gov-
ernment agencies in these countries consider the plight
of those affected by complications in the context of the
available clinical data.
Transabdominal mesh for POP: safety and efficacy
Women without a uterus
Both European and UK guidelines support the use of
sacrocolpopexy to treat PHVP [7, 60]. Vaginal alterna-
tives include vault suspension to the sacrospinous or
uterosacral ligaments, or introduction of a mesh device.
Whilst widely adopted in clinical practice, the evidence
base supporting sacrocolpopexy in preference to vaginal
alternatives deserves proper scrutiny. It has been noted
that there are twice as many published systematic re-
views of apical prolapse repair than there are RCTs used
within the reviews themselves [61].
A Cochrane review has strongly supported sacrocolpo-
pexy as superior to vaginal alternatives [23]. Data from
three RCTs suggested that women are more likely to be
aware of prolapse after a vaginal procedure (14% vs 7%;
RR 2.11; 95% CI = 1.06–4.21). From an anatomical per-
spective, authors found that 41% of women had recur-
rent prolapse after vaginal surgery as compared to 23%
after sacrocolpopexy. However, the studies used within
the Cochrane review are small and heterogenous and
utilised vaginal procedures that are not in widespread
routine use. The largest of the three studies included 53
patients and compared sacrocolpopexy to a total vaginal
mesh device not widely employed (Prolift®) [62]. Half of
the patients in one of the other studies by Benson et al.
(n = 42) underwent concurrent hysterectomy, raising
questions as to the applicability of these data in a review
of PHVP [63].
Data from four RCTs showed an increased likelihood
of repeat prolapse surgery for those who had a vaginal
procedure (5–18% vs. 4%; RR 2.28; 95% CI = 1.20–4.32).
This analysis used the data outlined above and outcomes
from a study limited to 12 months follow-up, comparing
sacrocolpopexy to uterosacral ligament suspension [64].
A retrospective comparative study has pooled data from
three large RCTs (n = 1022), authors concluded that
sacrocolpopexy offered an increased likelihood of suc-
cessful prolapse treatment as compared native tissue va-
ginal alternatives at 24 months (odds ratio (OR) = 6.00,
95% CI = 3.45–10.44) [65]. Success was strictly defined
as the absence of bothersome bulge symptoms, no pro-
lapse beyond the hymen, and no subsequent retreatment
of prolapse. However, a recent systematic review drew
more cautious conclusions and did not find a statistically
significant difference between the approaches [66]. Au-
thors noted that evidence tended to favour laparoscopic
sacrocolpopexy for some outcomes, such as satisfaction
and length of stay.
Systematic reviews suggest that the risk of mesh ero-
sion after sacrocolpopexy to be 2–3% [23, 66]. A large
multi-centre study of sacrocolpopexy with median
follow-up of 7 years modelled the risk of mesh erosion
from available data, estimating the rate erosion to be
10.5% [67]. However, this study used a range of mesh
materials according to the surgeons’ discretion, includ-
ing older heavier meshes that have been subsequently
abandoned.
Meta-analysis suggests that dyspareunia is significantly
more common after vaginal correction of apical prolapse
as compared to sacrocolpopexy (RR 2.53; 95% CI =
1.17–5.50) [23]. This may be due to changes in vaginal
axis or TVM used in some studies. Moderate quality evi-
dence from the Cochrane review suggested a higher like-
lihood of reported urinary incontinence after vaginal
procedures (RR 1.86, 95% CI 1.17 to 2.94). It is likely
that this finding is also related to differences in postop-
erative pelvic floor dynamics related to the surgical ap-
proach, irrespective of whether a mesh-augmented or
native tissue vaginal procedure is employed as a
comparator.
It would appear that sacrocolpopexy is at least com-
parable to vaginal alternatives and potentially allows for
better vault elevation optimising anatomical support and
symptomatic success. Nonetheless, functional superiority
across multiple domains, repeatedly cited in systematic
reviews, may not be as definitive as previously thought.
Women with a uterus
Studies suggest that up to 60% would prefer to retain
their uterus when undergoing surgery for uterine pro-
lapse [68]. Mesh hysteropexy allows for uterine preserva-
tion by suspending the uterus to the sacral promontory.
One RCT and one non-randomised prospective study
have compared vaginal hysterectomy, the current ‘gold
standard’ intervention, to ‘wrap round’ laparoscopic
sacrohysteropexy, which is a specific surgical variant of
the technique. These data demonstrated no difference in
patient-reported prolapse symptoms at 1 and 2 years
after surgery [69, 70]. Both the RCT and recent
meta-analysis report superior anatomical outcome fol-
lowing laparoscopic sacrohysteropexy, although how this
impacts on long-term objective and subjective outcome
is unknown [71]. Larger cohort studies of this approach
have shown 94% of patient report prolapse symptoms as
‘much better’ or ‘very much better’ in the medium term
and a 5% risk of repeat POP surgery at 2.6 years
follow-up [72, 73].
The UK’s NICE guidance concluded that there were
adequate safety and efficacy data supporting mesh hys-
teropexy, provided adequate clinical governance and
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audit processes [74]. As a relatively emergent operation,
much of these data are drawn from studies employing a
laparoscopic approach. A recent meta-analysis and a sys-
tematic review reported difficulties in formal statistical
analysis owing to the heterogeneity of outcome measures
and surgical techniques [71, 75]. Nonetheless, the re-
views demonstrated high rates of objective and subject-
ive success, associated with excellent patient satisfaction
rates, exceeding 90%.
As with some other applications of gynaecological
mesh, there is a lack of high-quality, long-term safety
data. The two largest cohort studies did not report any
cases of mesh erosion at median follow-up of almost
3 years; however, other cohorts report an incidence of
between 0 and 2.7% [72, 73, 76, 77]. One study reported
three cases (0.6%) of symptomatic intra-abdominal adhe-
sions attributed to non-peritonealised mesh [73]. Differ-
ences may well be driven by variations in surgical
technique. Most studies have failed to identify dyspar-
eunia or pelvic pain as an outcome measure. One study
(n = 110) reported similar rates of dyspareunia and pelvic
pain both preoperatively and postoperatively [72].
Subtotal hysterectomy with stump cervicopexy has
been shown in some studies to offer superiority to hys-
teropexy, without the risk of mesh erosion associated
with sacrocolpopexy. However, further research is re-
quired and meta-analyses have not supported such ad-
vantages. Rates of mesh erosion are higher with these
procedures than uterine sparing or native tissue alterna-
tives (OR 0.16; 95% CI, 0.03 to 0.97), without clear evi-
dence of anatomical or symptomatic superiority [71].
This is reflected in the UK NICE guidelines that recom-
mend the procedure is only undertaken in the context of
research or with special clinical governance, consent and
audit arrangements [78].
TVM for POP: efficacy and safety
A Cochrane meta-analysis in 2016 reviewed data from
studies involving absorbable and permanent synthetic
mesh, biological mesh and native tissue repair [25].
When compared to native tissue repair, data from 12
RCTs showed that mesh repair at 1 to 3 years is associ-
ated with a lower reported awareness of prolapse (RR
0.66; 95% CI 0.54 to 0.81). Additionally, women were
less likely to undergo repeat surgery for prolapse if mesh
was used (RR 0.53; CI 0.31 to 0.88). This is in contrast
to the findings from the largest RCT to date, the PRO-
SPECT trial [79]. This study did not report improved
outcomes associated with the use of mesh, and no differ-
ence in validated patient-reported outcome measures or
QoL measures at 1 to 3 years follow-up.
TVM for the primary repair of POP is not supported
by the European guidelines, national mesh reviews or
UK guidelines, due to high rates of mesh complications
[4, 5, 7]. A Cochrane review has reported a composite
risk of mesh exposure at 12%, with 8% of women under-
going surgical treatment [25]. Additionally, TVM was as-
sociated with higher rates of bladder injury and
new-onset SUI. The PROSPECT trial also reported a
mesh complication rate of 12%. A population-based co-
hort study that compared mesh and non-mesh proce-
dures for POP in Scotland over a 20-year period found a
substantially higher likelihood of late complications in
the cohort having mesh repair of anterior wall POP (ad-
justed incidence rate ratio 3·15; 95% CI 2.46–4.04) [58].
Managing adverse events attributed to mesh
A recurrent theme in both the Scottish Report and UK
Mesh Oversight Group Report was the failure of clini-
cians and regulators to recognise the existence of com-
plications due to mesh. Many women report feeling as if
their problems were dismissed or not taken seriously.
The Scottish Report has outlined the need for
multi-disciplinary working, patient-centred care, the col-
lection of long-term safety and efficacy data, and the de-
velopment of care pathways [5].
In an attempt to ensure high-quality care, 24 units in
the UK have identified themselves as having the expert-
ise to assess mesh complications. All centres have a
multi-disciplinary team comprising of a gynaecologist,
urologist, colorectal surgeon and pain management spe-
cialist, in addition to clinical nurse specialists and pelvic
floor physiotherapists. There is no agreed guidance as to
who should be referred to specialist centres. In the pri-
mary or secondary care setting, patients with signs or
symptoms of erosion or extrusion should be referred to
a specialist unit, as well as those not alleviated by con-
servative interventions. Further management is dictated
by the route of mesh insertion, mesh type and the nature
of the complication.
Cundiff et al. have systematically appraised the pub-
lished evidence for the treatment of AEs attributed to
gynaecological mesh, in an attempt to develop an
evidence-based algorithm [51]. The management of
complications lacks high-quality evidence to guide clini-
cians. Options include expectant and conservative man-
agement and partial and/or complete mesh excision. In
the absence of convincing evidence of extrusion into or
injury of adjacent organs, management requires careful
consideration. Mesh excision is technically demanding
and evidence to support surgery is lacking for many in-
dications. Particularly in the context of pain, it is import-
ant that patients are aware of a paucity of supportive
evidence before embarking on surgery. The management
of complications attributed to mesh after sacrohystero-
pexy was not reviewed by Cundiff et al. For pain attrib-
uted to adhesions between bowel and exposed mesh,
adhesiolysis and endoscopic re-peritonealisation has
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been described with success [73]. For exposed vaginal
mesh, authors have advocated expectant and office man-
agement with positive short-term results [76].
Conclusion
Gynaecological mesh has broadened the surgical options
available for the treatment of pelvic floor disorders with nu-
merous international and national reports appraising avail-
able data with respect to safety and efficacy [4, 6, 7, 45].
High-quality, long-term data support the use of TVM for
SUI in the form of the RPR MUT. Sacrocolpopexy for
PHVP is effective and safe, and may offer advantages over
vaginal alternatives; however, meta-analyses deserve closer
scrutiny. For uterine prolapse, good quality evidence from
short-term randomised studies and cohort studies support
the use of mesh hysteropexy. It is the most effective option
for uterine-sparing apical prolapse surgery, with a low com-
plication profile, although more high-quality, long-term
data are needed. Evidence supports advantages of a laparo-
scopic approach for both procedures.
The use of TVM for primary repair of POP is not sup-
ported by the available evidence. Data from the most re-
cent randomised trials have failed to show superiority
over native tissue repair, and TVM for POP is associated
with a high rate of mesh-specific SAEs. The treatment of
these complications is complex, and insufficient evi-
dence exists to confidently guide management. Reports
have consistently highlighted the human cost of
mesh-associated complications, and it is critically im-
portant that clinicians acknowledge this.
There has been a collective failure to regulate, appraise
and audit many mesh devices used to treat POP and
SUI. Going forward, further research is needed to clearly
define treatment benefit and inform the management of
complications attributed to mesh. In the interim,
multi-disciplinary, specialist centres should provide indi-
vidualised care that is evidence based where possible. Fi-
nally, clinicians in all care settings must recognise the
myriad of symptoms and complications attributed to,
and associated with, gynaecological mesh to ensure that
women who require treatment receive the care they
need.
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